Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.70 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7603135 | 0.86 | ADORA2B (0.70) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3186630 | 0.85 | PDE4A (0.94) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL11361392 | 0.84 | PDE4A (0.91) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7738361 | 0.84 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3108328 | 0.84 | ADORA2B (0.78) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL21381259 | 0.83 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL21381240 | 0.83 | ADORA2B (0.94) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3842077 | 0.83 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3106585 | 0.82 | ADORA2B (0.73) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7602652 | 0.82 | PDE4A (0.90) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| EP-1912992-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SmithKline Beecham Corporation (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017262-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | XDH, GPR84, GPR88 | PDE4A 315/4885PDE4B 578/4885PDE4C 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.